Revenue
0
2025-09-30 ·
Fundies. English
INMUNE BIO INC.
EDGARAnnual consolidated revenue for 2025: about uref_1269935354 50K, using the latest reported figures. The previous period, 2024, was about uref_1269935354 14K.
Latest quarter
- Cash and cash equivalents
- 24.8 million uref_1269935354 Source
Exact value
24751000 uref_1269935354
- Long-term debt including current maturities
- 15 million USD Source
Exact value
15000000 USD
- Shares outstanding
- 27.7 million uref_128578113 Source
Exact value
27653789 uref_128578113
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-10-29.
Financial data available through: 2025-12-31.
Coverage by financial measure
- Revenue: 2 of 11 periods available· newest 2025-12-31
- Operating income: 2 of 11 periods available· newest 2025-12-31
- Net income: 2 of 11 periods available· newest 2025-12-31
- Operating cash flow: 2 of 11 periods available· newest 2025-12-31
- Capital expenditure: 1 of 11 periods available· newest 2025-12-31
- Total assets: Multiple units; comparison withheld· newest 2025-12-31
- Total liabilities: Multiple units; comparison withheld· newest 2025-12-31
- Current assets: Multiple units; comparison withheld· newest 2025-12-31
- Current liabilities: Multiple units; comparison withheld· newest 2025-12-31
- Cash and cash equivalents: 2 of 11 periods available· newest 2025-12-31
- Long-term debt including current maturities: 3 of 11 periods available· newest 2024-12-31
- Shares outstanding: Multiple units; comparison withheld· newest 2025-12-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Revenue
+257.1%Prior period
uref_1269935354 14,000
–
Current period
uref_1269935354 50,000
–
Exact inputs and evidence
50000 − 14000 = 36000 uref_1269935354
14000 uref_1269935354 · 2024-01-01 – 2024-12-31
Inspect prior input Prior source50000 uref_1269935354 · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Net income
−uref_1269935354 3.8 millionPrior period
−uref_1269935354 42.1 million
–
Current period
−uref_1269935354 45.9 million
–
Exact inputs and evidence
-45900000 − -42100000 = -3800000 uref_1269935354
-42100000 uref_1269935354 · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-45900000 uref_1269935354 · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+uref_1269935354 10.8 millionPrior period
−uref_1269935354 33.4 million
–
Current period
−uref_1269935354 22.6 million
–
Exact inputs and evidence
-22600000 − -33400000 = 10800000 uref_1269935354
-33400000 uref_1269935354 · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-22600000 uref_1269935354 · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Capital expenditure.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
2025 2025-01-01 – 2025-12-31
- Revenue uref_1269935354 50,000 100% of revenue
- Operating costs Derived uref_1269935354 47.43 million 94,866% of revenue
- Operating income −uref_1269935354 47.38 million −94,766% of revenue
- Tax, interest and other Derived −uref_1269935354 1.48 million −2,966% of revenue
- Net income −uref_1269935354 45.9 million −91,800% of revenue
Cash
- Operating cash flow −uref_1269935354 22.6 million −45,200% of revenue
- Capital expenditure uref_1269935354 1.04 million 2,084% of revenue
- Free cash flow Derived −uref_1269935354 23.64 million −47,284% of revenue
Share of revenue by period
- Net income
- Tax, interest and other
- Operating costs
- 2024 Operating loss: operating costs were 304,636% of revenue.
- 2025 Operating loss: operating costs were 94,866% of revenue.
Values and sources
| Period | Revenue | Operating costs | Operating income | Tax, interest and other | Net income | Free cash flow | Source |
|---|---|---|---|---|---|---|---|
| 2024 2024-01-01 – 2024-12-31 | 14000 | 42649000 Derived | -42635000 | -535000 Derived | -42100000 | Unavailable | Source
|
| 2025 2025-01-01 – 2025-12-31 | 50000 | 47433000 Derived | -47383000 | -1483000 Derived | -45900000 | -23642000 Derived | Source
|
Amounts are exact, in uref_1269935354.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
uref_1269935354 50K 2025
Values and sources
| Period | Series | Value(uref_1269935354) | Source evidence |
|---|---|---|---|
| 2024 | Revenue | 14000 |
|
| 2025 | Revenue | 50000 |
|
Revenue growth
Change in revenue from the same financial period one year earlier.
257.1% 2025
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2024 | Year over year | No prior comparable period |
|
| 2025 | Year over year | 257.1% |
|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Operating margin -94,766% 2025
Net margin -91,800% 2025
Free cash flow margin -47,284% 2025
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2024 | Operating margin | -304,535.7% |
|
| 2025 | Operating margin | -94,766% |
|
| 2024 | Net margin | -300,714.3% |
|
| 2025 | Net margin | -91,800% |
|
| 2024 | Free cash flow margin | Not reported |
|
| 2025 | Free cash flow margin | -47,284% |
|
Operating cash flow
Cash generated by the company’s normal business operations.
uref_1269935354 -22.6M 2025
Values and sources
| Period | Series | Value(uref_1269935354) | Source evidence |
|---|---|---|---|
| 2024 | Operating cash flow | -33400000 |
|
| 2025 | Operating cash flow | -22600000 |
|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
uref_1269935354 -23.6M 2025
Values and sources
| Period | Series | Value(uref_1269935354) | Source evidence |
|---|---|---|---|
| 2024 | Free cash flow | Unavailable |
|
| 2025 | Free cash flow | -23642000 |
|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2024-12-31 | Liabilities / assets | Not reported | No source recorded |
| 2025-12-31 | Liabilities / assets | Not reported | No source recorded |
Current assets to current liabilities
Current assets divided by current liabilities.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2024-12-31 | Current assets / current liabilities | Not reported | No source recorded |
| 2025-12-31 | Current assets / current liabilities | Not reported | No source recorded |
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2024 2024-01-01 – 2024-12-31 | −uref_1269935354 42.1 million Exact valueExact value: -42100000 uref_1269935354 Share or citeThe citation records this snapshot. The page link may show a newer release later. | −uref_1269935354 33.4 million Exact valueExact value: -33400000 uref_1269935354 Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2025 2025-01-01 – 2025-12-31 | −uref_1269935354 45.9 million Exact valueExact value: -45900000 uref_1269935354 Share or citeThe citation records this snapshot. The page link may show a newer release later. | −uref_1269935354 22.6 million Exact valueExact value: -22600000 uref_1269935354 Share or citeThe citation records this snapshot. The page link may show a newer release later. | uref_1269935354 1.04 million Exact valueExact value: 1042000 uref_1269935354 Share or citeThe citation records this snapshot. The page link may show a newer release later. | −uref_1269935354 23.64 million Calculation and evidence-22600000 − 1042000 uref_1269935354 Exact free cash flow: -23642000 uref_1269935354
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
48 filings · 1,912 latest values · 1,912 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001711754, 1711754, INMB, edgar:1711754, inmb
Also known as INMUNE BIO INC., Inmune Bio, Inc.